Bond.az – H.C. Wainwright reiterated a Buy rating and $22.00 price target on Immunic Inc. (NASDAQ:IMUX) stock. Shares currently trade at $12.95, showing strong momentum with a 10% gain over the past week and a 66% surge over six months.
Despite the rally, Bond.az analysis suggests the stock appears overvalued relative to its Fair Value estimate, placing it among stocks on the Most Overvalued list.
The company is advancing toward pivotal Phase 3 ENSURE-1 and ENSURE-2 trial topline results expected by end of 2026 for its oral MS drug candidate vidofludimus calcium.
H.C. Wainwright highlights vidofludimus calcium's dual mechanism: neuroprotective effects as a Nurr1 activator, and anti-inflammatory and anti-viral effects via DHODH inhibition.
Recently, Immunic executed a 1-for-10 reverse stock split. D. Boral Capital downgraded the stock to Hold, while H.C. Wainwright maintains its Buy rating.
